key: cord-0891465-q8aewj9s authors: Zhu, Huolan; Zhang, Yanfei; Pei, Zuowei; Guo, Ying; Yang, Chenguang; Song, Yan; Guo, Xiaomei; Wang, Fang title: Manifestation of cardiac injury in hospitalised patients with COVID‐19 date: 2021-04-12 journal: Int J Clin Pract DOI: 10.1111/ijcp.14197 sha: ae36fffa96a79e2846fce688aaebf5192804c288 doc_id: 891465 cord_uid: q8aewj9s BACKGROUND: COVID‐19 has been sweeping the world since it emerged in late December 2019. However, little is known about cardiac injury in hospitalised COVID‐19 patients. This study is to investigate the incidence and characteristics of myocardial injury in COVID‐19 patients admitted in hospital. METHODS: Fifty‐four COVID‐19 patients were enrolled in one ward in Tongji Hospital, Wuhan, China, and 5 were excluded caused by missing cardiac troponin I levels. Forty‐nine participants were included in the final analysis. The clinical manifestations of hospitalised patients were analysed. Patients were divided into two groups, cardiac injury group and non‐cardiac injury group, based on whether cardiac troponin I was elevated. Epidemic characteristics and laboratory test results were analysed in these two group. RESULTS: The average age of patients in the cardiac injury group was older (68.0 years old) than that in the non‐cardiac injury group (61.5 years old). The percentages of patients with diabetes and critically severe pneumonia in the cardiac injury group were 38.5% and 38.5% respectively. Lymphocytes were decreased in 53.1% of all enrolled patients, but this decrease was more prominent (76.9%) in the cardiac injury group than the non‐cardiac injury group (44.4%). Patients in the cardiac injury group also had lower platelet counts. CONCLUSIONS: COVID‐19 can cause cardiac injury in many patients. It is more common in older patients and patients with diabetes and is associated with a significant decrease in lymphocytes. I was elevated. Epidemic characteristics and laboratory test results were analysed in these two group. The average age of patients in the cardiac injury group was older (68.0 years old) than that in the non-cardiac injury group (61.5 years old). The percentages of patients with diabetes and critically severe pneumonia in the cardiac injury group were 38.5% and 38.5% respectively. Lymphocytes were decreased in 53.1% of all enrolled patients, but this decrease was more prominent (76.9%) in the cardiac injury group than the non-cardiac injury group (44.4%). Patients in the cardiac injury group also had lower platelet counts. Conclusions: COVID-19 can cause cardiac injury in many patients. It is more common in older patients and patients with diabetes and is associated with a significant decrease in lymphocytes. A comprehensive understanding of COVID-19, the emergent hygeian issue, is essential for its treatment. COVID-19 can damage vital organs and systems, like cardiovascular system, in addition to the respiratory system. Understanding the myocardial damage of COVID-19 is very important for clinicians to control this disease. COVID-19 has been spreading wildly since its outbreak in late December 2019 in Wuhan, China. With more and more studies reported, it has been found that COVID-19 can damage multiple systems and organs in addition to the respiratory system. [1] [2] [3] In hospital patients, Cardiac injury is a common condition and it is associated with higher risk of in-hospital mortality. 4 One study found that cardiac injury occurred in 12% of COVID-19 patients, 2 and another has indicated that COVID-19 patients with cardiovascular disease are at greater risk for cardiac injury. 5 The population with cardiovascular disease is a precisely defined, large base group. 6 COVID-19 could also cause fulminant myocarditis. 7 In our clinical observation, it was also found that COVID- 19 This was a single-centre retrospective study. In this study, COVID-19 patients were enrolled after being admitted to East Ward 11 of Tongji Hospital from February 10 to February 23, 2020. All COVID-19 patients in the ward were enrolled. Oral consent was obtained from the patients, and the patients' written consents were waived. Tongji Hospital is the national designated hospital for admission of COVID-19 patients. All patients were diagnosed according to WHO guidelines. 8 The study has been approved by the ethics committees of Tongji Hospital and Beijing Hospital. All patients were under the charge of Professor Wang Fang's team. We recorded the patients' clinical features: age, sex, disease history, onset duration, exposure history, severity (mild, severe and critically severe), diabetes, hyperlipidaemia and cardiovascular disease. We also recorded the patients' symptoms and results of physical examination: fever, cough, sore throat, fatigue, myalgia, headache, diarrhoea, chest congestion, shortness of breath, palpitation, blood pressure, heart rate and respiratory rate. The following laboratory tests were also recorded: routine blood test, liver and kidney function, coagulation function, d-dimer, C-reactive protein, erythrocyte sedimentation rate (ESR) and procalcitonin. In particular, we recorded the test findings closely relating to cardiac injury: cardiac troponin I (cTn I), N terminal brain natriuretic peptide (NT-BNP) and CT scans. Pericardial effusion and heart shadow enlargement were observed by CT scan with the patient in the supine position. Onset duration was defined as the date from symptom discovery to hospitalisation. Cardiac injury was defined as serum level of troponin I above the 99th percentile of the reference limit. Severity was defined as: mild: non-pneumonia or mild pneumonia; severe: respiratory frequency ≥30/minute, blood oxygen saturation ≤93%, PaO2/ FiO2 ratio [the ratio between arterial oxygen partial pressure and fractional inspired oxygen] <300 and/or lung infiltrates >50% within 24 to 48 hours; or critically severe: respiratory failure, septic shock and/or multiple organ dysfunction. 9 Throat swab specimens were obtained from all patients, and COVID-19 was tested for by RT-PCR according to the instructions. Fifty-four patients were enrolled, and 5 were excluded because of missing cardiac troponin I levels. The study ended up with 49 patients in the final analysis. The average age of patients was 63 years old. Patients in the cardiac injury group were significantly older than patients in the non-cardiac injury group. The mean age of the cardiac injury group was 68 years old, and that of the non-cardiac injury group was 61.5 years old. There was no difference between the groups in onset duration, gender or history of exposure. In terms of severity of the disease, the proportion of patients with critically severe pneumonia was significantly higher in the cardiac injury group than that in the non-cardiac injury group. Critically severe COVID-19 pneumonia occurred in 5 of 13 patients in the cardiac injury group (38.5%) and in 3 of 36 patients in the non-cardiac injury group (11.1%). There was no difference between the two groups in occurrence of chronic diseases such as hyperlipidaemia, hypertension or cardiovascular disease. In the cardiac injury group, the rate of diabetes was higher than in the other group. Of the 13 patients with cardiac injury, 5 were diabetic (38.5%) ( Table 1 ). The symptom of fever appeared in 77.55% of enrolled patients, and cough and fatigue appeared in 69.39% and 59.18% of enrolled patients respectively. Chest tightness appeared in 32.65% and palpitation appeared in 32.65% of the study population, with no difference between the two groups for either of these symptoms. There was no significant difference in the percentage of patients with any other symptoms between the two groups ( Table 2) . Table 3 (at the end of the text) shows the laboratory test results. The rate of abnormal leucocyte levels was 38.8% in the whole population, and lymphocytic decline happened in 53.1% of patents. Moreover, reduction in lymphocyte levels was found significantly more frequently in the cardiac injury group (76.9%) than the noncardiac injury group (44.4%). Patients with cardiac injury also had significantly fewer platelets than patients without cardiac injury. The coagulation function of fibrinogen increased in 71.4% of all patients with no difference between the groups. Thromboplastin time decreased in 98% of all patients. d-dimer increased in 79.6% of the population, with no difference between the two groups. C-reactive protein and blood sedimentation rate increased in patients with and without cardiac injury in 95.9% and 77.6% of cases respectively. Serum electrolytes and blood glucose showed no significant differences between the two groups. had an enlarged heart shadow. Pericardial effusion was present in 1 patient (Figure 1 ). The histogram in Figure 2 shows the proportion of indicators associated with cardiac injury. The box plot in Figure 3 shows the range of parameters associated with cardiac injury in both groups. The study population was limited to those admitted to a particular ward. Patients transferred directly to the intensive care unit were not included in the study, and some mild cases were not observed because they were not admitted to the hospital, leading to missing data. A larger sample size and a larger scope of study can provide more intact data on cardiac injury caused by COVID-19. In our daily clinical practice, we found that patients with cardiac injury are also prone to arrhythmia and heart failure. Based on our experience, we used a large dose of vitamin C in addition to antiarrhythmia drugs and anti-heart failure drugs. The patients' symptoms improved. Yet the main goal remains the comprehensive treatment of COVID-19 itself. We acknowledge the help provided by Liang Zhao, Analysis Department of Bestnovo Company of statistical analysis support. Oral consent was obtained from the patients, and the patients' written consents were waived. The study has been approved by the ethics committees of Tongji Hospital and Beijing Hospital. The authors declare that they have no competing interests. YZ collated the patients' data. ZP and YG contributed to the writing. CY contributed to the data analysis. YS, XG and FW were in charge of the patients. FW conceived and supervised the study. HZ was a major contributor in writing the manuscript. All authors read and approved the final manuscript. Data are available from the corresponding author upon reasonable request. Huolan Zhu https://orcid.org/0000-0002-9845-4494 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Clinical features of patients infected with 2019 novel coronavirus in Wuhan Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin Interpretation of "guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the National Health Commission (Trial Version 5 Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Viral myocarditisdiagnosis, treatment options, and current controversies Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection Benefits of flu vaccination for persons with diabetes mellitus: a review Diabetes and COVID-19 Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Pathological findings of COVID-19 associated with acute respiratory distress syndrome The clinical and chest CT features associated with severe and critical COVID-19 pneumonia Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care Manifestation of cardiac injury in hospitalised patients with COVID-19